Last Price$70.5(2.1%)
Market Cap$13.4B
LTM Return on Capital Employed (ROCE)
5.5%
5Y avg
4.2%
Biotechnology industry
median
(52.0%)
Stock quality & Intrinsic value
7/10
(0.3%) overvalued
BioMarin Pharmaceutical Inc. Return on Capital Employed (ROCE)
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Capital Employed (ROCE) | (54.2%) | (16.7%) | (9.9%) | 4.9% | 1.9% | 22.6% | (3.7%) | (8.0%) | (8.9%) | (4.7%) | (4.6%) | (17.5%) | (2.6%) | (1.5%) | (1.4%) | 17.7% | (0.9%) | 0.9% | 3.0% | 6.1% |
Overvalued or undervalued?
Check the intrinsic value for BMRN
and see if it's the right time to invest.
BioMarin Pharmaceutical Inc. (BMRN) Return on Capital Employed (ROCE) comparison analysis
General
LTM Return on Capital Employed (ROCE)
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
BioMarin Pharmaceutical Inc.BMRN
5.5%
18.0%
139.3%
15.0%
Median Peer Set
(5.8%)
13.2%
(41.2%)
0.4%
United Therapeutics CorporationUTHR
16.0%
23.6%
25.7%
41.5%
Regeneron Pharmaceuticals, Inc.REGN
10.3%
8.3%
10.4%
31.1%
Royalty Pharma plcRPRX
6.4%
(3.8%)
(43.7%)
37.9%
Alnylam Pharmaceuticals, Inc.ALNY
(2.6%)
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals IncorporatedVRTX
(5.5%)
11.7%
N/A
(4.9%)
Incyte CorporationINCY
(6.1%)
14.8%
(94.0%)
0.8%
BioNTech SEBNTX
(6.5%)
(77.4%)
(89.7%)
24.4%
argenx SEARGX
(8.5%)
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
(27.4%)
73.7%
467.1%
(35.9%)
Summit Therapeutics Inc.SMMT
(51.1%)
N/A
(68.7%)
N/A
BMRN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 25.7 37.7% | 84.2 228.1% | 121.6 44.4% | 296.5 143.9% | 324.7 9.5% | 376.3 15.9% | 441.4 17.3% | 500.7 13.5% | 548.5 9.5% | 751.0 36.9% | 889.9 18.5% | 1,116.9 25.5% | 1,313.6 17.6% | 1,491.2 13.5% | 1,704.0 14.3% | 1,860.5 9.2% | 1,846.3 (0.8%) | 2,096.0 13.5% | 2,419.2 15.4% | 2,853.9 18.0% |
| Cost of Goods Sold (COGS) | 2.6 | 8.7 | 18.4 | 52.5 | 65.9 | 70.3 | 84.0 | 91.8 | 95.7 | 129.8 | 152.0 | 209.6 | 241.8 | 315.3 | 359.5 | 524.3 | 470.5 | 483.7 | 577.1 | 580.2 |
% margin | 23.0 89.8% | 75.5 89.6% | 103.2 84.9% | 244.0 82.3% | 258.7 79.7% | 306.0 81.3% | 357.3 81.0% | 408.9 81.7% | 452.7 82.5% | 621.3 82.7% | 737.9 82.9% | 907.2 81.2% | 1,071.9 81.6% | 1,175.9 78.9% | 1,344.6 78.9% | 1,336.2 71.8% | 1,375.8 74.5% | 1,612.4 76.9% | 1,842.2 76.1% | 2,273.7 79.7% |
| Operating Expenses | 87.3 | 100.1 | 160.5 | 204.2 | 242.3 | 299.0 | 389.8 | 519.1 | 608.8 | 781.7 | 1,019.4 | 1,111.5 | 1,211.6 | 1,349.5 | 1,470.0 | 1,432.4 | 1,458.1 | 1,570.8 | 1,746.3 | 1,789.5 |
| Research & Development Expenses (R&D) | 56.4 | 66.7 | 78.6 | 93.3 | 115.1 | 147.3 | 214.4 | 302.2 | 354.8 | 461.5 | 634.8 | 661.9 | 610.8 | 696.3 | 715.0 | 628.1 | 628.8 | 649.6 | 746.8 | 747.2 |
| Selling, General & Administrative Expenses (SG&A) | 41.6 | 49.0 | 77.5 | 106.6 | 124.3 | 151.7 | 175.4 | 198.2 | 235.4 | 302.2 | 402.3 | 476.6 | 554.3 | 604.4 | 680.9 | 737.7 | 759.4 | 854.0 | 937.3 | 1,009.0 |
% margin | (64.2) (250.2%) | (24.7) (29.3%) | (57.3) (47.1%) | 39.8 13.4% | 16.4 5.1% | 0.5 0.1% | (33.9) (7.7%) | (110.2) (22.0%) | (156.0) (28.4%) | (92.9) (12.4%) | (110.7) (12.4%) | (803.4) (71.9%) | (14.7) (1.1%) | (123.5) (8.3%) | (125.5) (7.4%) | (96.3) (5.2%) | (60.0) (3.3%) | 57.5 2.7% | 194.4 8.0% | 484.2 17.0% |
| Interest Income | 1.9 | 12.9 | 0.0 | 16.4 | 5.1 | 4.1 | 2.9 | 2.6 | 3.1 | 5.9 | 4.5 | 7.5 | 14.9 | 22.8 | 22.7 | 16.6 | 10.5 | 18.0 | 58.3 | 74.9 |
| Interest Expense | 11.9 | 16.7 | 0.0 | 16.4 | 14.1 | 10.3 | 8.3 | 7.6 | 10.4 | 36.6 | 38.2 | 39.5 | 42.7 | 43.7 | 23.5 | 29.3 | 15.3 | 16.0 | 17.3 | 12.3 |
| Pre-tax Income | (74.3) | (28.5) | (15.1) | 33.4 | 0.6 | (21.5) | (43.6) | (118.3) | (176.5) | (124.9) | (154.7) | (831.1) | (35.9) | (142.7) | (94.8) | (42.3) | (75.4) | 149.6 | 188.6 | 541.8 |
% effective tax rate | 21.9 (29.5%) | 23.1 (81.1%) | 0.7 (4.8%) | 2.6 7.8% | 1.1 186.2% | (227.3) 1,057.7% | 10.2 (23.4%) | (3.9) 3.3% | (0.2) 0.1% | 9.1 (7.3%) | 17.1 (11.0%) | (200.8) 24.2% | 81.2 (226.2%) | (65.5) 45.9% | (71.0) 74.8% | (901.4) 2,129.9% | (11.3) 15.0% | 8.0 5.4% | 20.9 11.1% | 114.9 21.2% |
% margin | (74.3) (289.3%) | (28.5) (33.9%) | (15.8) (13.0%) | 30.8 10.4% | (0.5) (0.2%) | 205.8 54.7% | (53.8) (12.2%) | (114.3) (22.8%) | (176.4) (32.2%) | (134.0) (17.8%) | (171.8) (19.3%) | (630.2) (56.4%) | (117.0) (8.9%) | (77.2) (5.2%) | (23.8) (1.4%) | 854.0 45.9% | (64.1) (3.5%) | 141.6 6.8% | 167.6 6.9% | 426.9 15.0% |
| EPS | (1.08) | (0.34) | (0.16) | 0.31 | (0.00) | 1.99 | (0.48) | (0.95) | (1.28) | (0.92) | (1.07) | (3.80) | (0.67) | (0.44) | (0.13) | 4.75 | (0.35) | 0.76 | 0.89 | 2.13 |
| Diluted EPS | (1.08) | (0.34) | (0.16) | 0.29 | (0.00) | 1.73 | (0.48) | (0.95) | (1.28) | (0.92) | (1.07) | (3.79) | (0.67) | (0.44) | (0.13) | 4.53 | (0.35) | 0.75 | 0.87 | 2.06 |
% margin | (54.5) (212.2%) | (14.9) (17.7%) | (57.3) (47.1%) | 67.4 22.7% | 35.6 11.0% | 17.1 4.5% | (0.2) (0.0%) | (79.8) (15.9%) | (137.4) (25.0%) | (50.0) (6.7%) | (110.7) (12.4%) | (705.5) (63.2%) | 94.8 7.2% | (3.5) (0.2%) | 33.9 2.0% | (5.9) (0.3%) | 48.0 2.6% | 267.5 12.8% | 310.3 12.8% | 650.5 22.8% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is BioMarin Pharmaceutical Inc.'s Return on Capital Employed (ROCE)?
As of today, Microsoft Corp's last 12-month Return on Capital Employed (ROCE) is 5.5%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Return on Capital Employed (ROCE) for BioMarin Pharmaceutical Inc. have been 2.3% over the past three years, and 4.4% over the past five years.
2) Is BioMarin Pharmaceutical Inc.'s Return on Capital Employed (ROCE) Good?
As of today, BioMarin Pharmaceutical Inc.'s Return on Capital Employed (ROCE) is 5.5%, which is higher than industry median of (52.0%). It indicates that BioMarin Pharmaceutical Inc.'s Return on Capital Employed (ROCE) is Good.